Navigation Links
Marina Biotech, Inc. Joins OTCQX
Date:2/2/2012

NEW YORK, Feb. 2, 2012 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), the company that operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks, today announced that Marina Biotech, Inc. (OTCQX: MRNA), a company focused on oligonucleotide-based therapeutics, is now trading on the OTC market's highest tier, OTCQX®.   

(Logo:  http://photos.prnewswire.com/prnh/20110118/MM31963LOGO )

Marina Biotech began trading today on the OTC market's prestigious tier, OTCQX U.S. Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

"Marina Biotech has chosen to remain investor focused as they transition to trade on OTCQX, which allows them to continue to provide superior information and transparent trading on the quality-controlled OTCQX platform," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome Marina Biotech to OTCQX."

Pryor Cashman LLP will serve as Marina Biotech's Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing guidance on OTCQX requirements.

About Marina Biotech, Inc.

Marina Biotech, Inc. (OTCQX: MRNA) trades in the United States on OTCQX under the symbol "MRNA". Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference and messenger RNA translational blocking.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks.  Our OTC Link platform supports an open network of competing broker-dealers that provide investors with the best prices in over 10,000 OTC securities.  We categorize the wide spectrum of OTC companies into three tiers - OTCQX (the quality-controlled marketplace for investor friendly companies), OTCQB® (the U.S. reporting company marketplace for development stage companies), and OTC Pink (the speculative trading marketplace) - so investors can identify the level and quality of information companies provide.  To learn more about how OTC Markets Group makes the unlisted markets more transparent, informed, and efficient, visit www.otcmarkets.com.

Subscribe to the OTCQX RSS Feed


'/>"/>
SOURCE OTC Markets Group Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
2. Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement
3. FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI® Supplemental Biologic License Application
4. C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc
5. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
6. For the First Time, a Glioma - Brain Cancer - may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
7. For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
8. Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Companys First Annual 2010 Micro Cap Conference
9. Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets
10. Ganeden Biotech, Liquid Health Labs Unveil New Drink Technology
11. Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
Breaking Biology News(10 mins):